Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets

Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for
Simvastatin Tablets
-- This Approval Creates New Growth Opportunities for the Company

CHENGDU, China, July 31 /Xinhua-PRNewswire-FirstCall/ -- Tianyin
Pharmaceutical, Co., Inc. (OTC Bulletin Board: TYNP), a manufacturer and
supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu,
China, today announced that it has received approval from the Chinese State
Food and Drug Administration (SFDA) to produce Simvastatin Tablets (SFDA
approval number H20083478).
Simvastatin is a Statin drug which is used to control hypercholesterolemia
and treat coronary heart diseases. This is the only Statin type drug approved
by SFDA to treat these conditions and is highly effective, with fewer side
effects when compared to other similar drugs. Simvastatin can reduce the
mortality rate of coronary heart diseases, coronary artery diseases, and
cerebral stroke by 17%, 24% and 25%, respectively. The China Cholesterol
Education Program recommends Simvastatin to treat these conditions.
Simvastatin is also listed in the National Medical Insurance Program, thus
allowing insured patients to receive reimbursement for the costs of this
prescription.
Research report from Tulane University published on American Heart
Association's Journal of Circulation shows that due to lifestyle changes in
China, high levels of hypercholesterolemia and low levels of awareness,
treatment, and information regarding same has made cardiovascular disease the
leading cause of death in China. As a leading Statin class drug, Simvastatin
had total sales of over $190 million in China during 2006. Less than 40% of
Simvastatin sold in China's market is produced by domestic manufacturers.
Simvastatin Tablets from Tianyin are expected to gain large market share from
companies that currently import Simvastatin due to Tianyin's competitive
pricing advantages.
Tianyin's Simvastatin Tablets are sold by prescription in hospitals, which
is the major sales channel for drugs in China. Tianyin will start producing
Simvastatin Tablets in early August, while selling it through our strategic
distributor partners throughout China.
"We are very pleased to receive approval of Simvastatin from the Chinese
SFDA, a very important step and positive progress for our business which
further diversifies and complements our product portfolio," Dr. Jiang,
Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. "This
favorable decision by the SFDA provides further evidence of our ability to get
drugs through the approval process and to market. We are optimistic that the
additional drugs that are currently in our development pipeline for SFDA
approval will be able to move through this process toward commercialization."
"We are well positioned to take advantage of this new growth opportunity.
This approval will enable us to immediately leverage our production capacity
and distribution network to facilitate commercialization of this new drug. We
expect to begin production of record revenues of Simvastatin Tablets by August
2008 and currently maintain the capacity to produce approximately $2 million
of this product annually. The margin profile is anticipated to be slightly
better than our current product mix. We will be announcing our June 30, 2008
year end earnings date in the near term but we would like to reiterate that
the company expects to exceed its FY2008 make good of $5.6 million in net
income or fully diluted EPS of $0.16 per share," concluded Dr. Jiang.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese
Medicine ("TCM") in China. It was established in 1994 and acquired by the
current management team in August 2003. It has a comprehensive product
portfolio of 34 modernized TCMs in the market, 22 of which are listed in the
highly selective National Medicine Catalog of the National Medical Insurance
Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D
platform supported by leading Chinese academic institutions. The Company has a
pipeline of 51 pharmaceutical products pending approval. Tianyin has an
extensive nationwide distribution network throughout China with a sales force
of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with
two manufacturing facilities and a total of 1,187 employees. Tianyin achieved
revenue of $20.4 million and net income of $3.95 million in FY2007 ending June
30, 2007. For more information about Tianyin Pharmaceuticals, please visit
http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company's filings with the
Securities and Exchange Commission.
For more information, please contact:

For the Company:
Allen Tang, Ph.D., MBA, Assistant to the CEO
China
Tel: +86-158-2122-5642
Email: Allen.y.tang@gmail.com

Investors:
HC International, Inc.
Alan Sheinwald
US
Tel: +1-914-669-0222
Email: Alan.Sheinwald@hcinternational.net

SOURCE Tianyin Pharmaceutical, Co., Inc.

For the Company, Allen Tang, Ph.D., MBA, Assistant to the CEO, China,
+86-158-2122-5642, or Allen.y.tang@gmail.com; Investors, Alan Sheinwald of HC
International, Inc., US, +1-914-669-0222, or
Alan.Sheinwald@hcinternational.net, both for Tianyin Pharmaceutical, Co.,
Inc.